<p>佛羅里達州朱庇特，2025 年 12 月 15 日（全球新聞通訊社）—— <strong>Dyadic Applied BioSolutions（“Dyadic”）（納斯達克：DYAI）</strong> 是一家全球生物技術公司，專注於在生命科學、食品與營養以及生物工業市場中生產精確工程化的無動物蛋白和酶。今天宣佈與 Opes Diagnostics Limited（“Opes”）達成商業協議，以支持 Dyadic 重組人轉鐵蛋白、牛轉鐵蛋白、人 FGF 和牛 FGF 產品在無血清細胞培養基應用中的商業推出。</p>
<p>根據協議，Opes 將利用其現有的商業關係和市場經驗，主要在歐洲、以色列和亞洲識別和接觸潛在客户，以加速 Dyadic 重組蛋白產品在細胞培養基及相關應用中的市場進入，同時 Dyadic 保留直接銷售和與全球其他合作伙伴合作的能力。</p>
<p>此次合作旨在加速 Dyadic 利用其微生物表達平台生產的重組蛋白產品在研究、診斷、培養肉和生命科學生物製造等行業的滲透，這些行業需要可靠、可擴展且具有成本效益的生長因子和功能性蛋白來源。Opes 已經為多家使用無血清細胞培養基的客户提供了樣品，應用於生命科學、食品和營養領域。</p>
<p>“這次合作通過與在我們服務的行業中擁有強大現有關係的合作伙伴擴展我們的重組蛋白產品組合，支持我們的商業目標，” Dyadic Applied BioSolutions 總裁兼首席運營官 Joe Hazelton 表示。“Opes 的市場存在和客户網絡預計將有助於推動 Dyadic 細胞培養基產品在不斷擴展的市場中的採用，並進一步推動我們從主要的開發活動轉向更廣泛的商業參與。”</p>
<p><strong>關於 Dyadic Applied BioSolutions</strong></p>
<p>Dyadic Applied BioSolutions 是一家全球生物技術公司，利用其專有的微生物平台生產重組蛋白，這些蛋白被銷售或授權給生命科學、食品與營養以及生物工業市場的合作伙伴。這些高質量的蛋白旨在幫助客户開發更高效、可擴展和可持續的產品。Dyadic 的 C1 和 Dapibus™表達系統支持靈活、具有成本效益的製造，並且是不斷增長的商業和合作項目組合的基礎。有關 Dyadic 的更多信息，請訪問 www.dyadic.com</p>
<p><strong>關於 Opes Diagnostics Limited</strong></p>
<p>Opes Diagnostics Limited 是一家總部位於英國的診斷工具、實驗室耗材和生物試劑的提供商，在歐洲和其他國際市場上擁有成熟的客户關係。Opes 為生物技術、診斷及相關領域的一系列產品提供商業化支持。</p>
<p><strong>前瞻性聲明的安全港</strong></p>
<p>本新聞稿包含根據《證券法》第 27A 節和《交易法》第 21E 節的定義的前瞻性聲明，包括 Dyadic 對未來事件或未來財務表現的預期、意圖、策略和信念，例如 Dyadic 臨牀試驗的成功及其蛋白生產平台的興趣、Dyadic 的研究項目和第三方合作，以及必要資金的可用性。前瞻性聲明涉及許多超出 Dyadic 控制的風險、不確定性或其他因素。這些因素包括但不限於以下內容：（i）Dyadic 的淨虧損歷史；（ii）市場和監管對 Dyadic 微生物蛋白生產平台及其他技術的接受；（iii）未能商業化 Dyadic 的微生物蛋白生產平台或其他技術；（iv）競爭，包括來自替代技術的競爭；（v）非臨牀研究和臨牀試驗的結果；（vi）Dyadic 的資本需求；（vii）全球經濟和金融狀況的變化；（viii）Dyadic 對信息技術的依賴；（ix）Dyadic 對第三方的依賴；（x）政府法規及環境、社會和治理問題；（xi）知識產權風險；（xii）Dyadic 遵守納斯達克證券市場上市標準的能力。有關可能導致 Dyadic 實際結果與其當前預期不同的風險的更完整描述，請參見 Dyadic 提交給 SEC 的 10-K 年報和 10-Q 季度報告中的 “風險因素” 部分，這些因素可能會不時在 Dyadic 定期向 SEC 提交的文件中更新，這些文件可在 SEC 網站和 www.dyadic.com 上獲取。所有前瞻性聲明僅在發佈之日有效，除非法律要求，Dyadic 不承擔在本新聞稿發佈後出於任何原因公開更新任何此類前瞻性聲明以使其與實際結果或 Dyadic 的預期變化相符的義務。</p>
<p>媒體聯繫人：</p>
<p>Dyadic Applied BioSolutions：</p>
<p>Ping Rawson</p>
<p>首席財務官</p>
<p>電話：（561）743-8333</p>
<p>電子郵件：ir@dyadic.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UazJOU00zTXpJeE1qZzVJekl3TVRreU1UQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UazJOU00zTXpJeE1qZzVJekl3TVRreU1UQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png"/></p>

DYAI

<p>Dyadic Applied BioSolutions 與 Opes Diagnostics Limited 達成了一項商業協議，以支持 Dyadic 在生命科學、食品和營養市場推出重組蛋白用於無血清細胞培養基。Opes 將利用其市場經驗在歐洲、以色列和亞洲識別潛在客户。此次合作旨在加速 Dyadic 蛋白產品在研究、診斷和生物製造等各個行業的應用</p>

<p>JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- <strong>Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI)</strong>, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food &amp; nutrition, and bioindustrial markets today announced that it has entered into a commercial agreement with Opes Diagnostics Limited (“Opes”) to support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products for use in serum-free cell culture media applications in the life science, food and nutrition markets.</p>
<div class="lb-trans"><p>佛羅里達州朱庇特，2025 年 12 月 15 日（全球新聞通訊社）—— <strong>Dyadic Applied BioSolutions（“Dyadic”）（納斯達克：DYAI）</strong> 是一家全球生物技術公司，專注於在生命科學、食品與營養以及生物工業市場中生產精確工程化的無動物蛋白和酶。今天宣佈與 Opes Diagnostics Limited（“Opes”）達成商業協議，以支持 Dyadic 重組人轉鐵蛋白、牛轉鐵蛋白、人 FGF 和牛 FGF 產品在無血清細胞培養基應用中的商業推出。</p>
</div><p>Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate market entry for Dyadic’s recombinant protein portfolio in cell culture media and related applications, while Dyadic retains the ability to sell directly and to work with additional partners globally.</p>
<div class="lb-trans"><p>根據協議，Opes 將利用其現有的商業關係和市場經驗，主要在歐洲、以色列和亞洲識別和接觸潛在客户，以加速 Dyadic 重組蛋白產品在細胞培養基及相關應用中的市場進入，同時 Dyadic 保留直接銷售和與全球其他合作伙伴合作的能力。</p>
</div><p>The collaboration is intended to accelerate the penetration of Dyadic’s recombinant protein products produced using its microbial expression platforms in industries including research, diagnostics, cultured meat and life sciences biomanufacturing that require reliable, scalable, and cost-effective sources of growth factors and functional proteins. Opes has already sampled multiple customers utilizing serum free cell culture media in life sciences, food and nutrition applications.</p>
<div class="lb-trans"><p>此次合作旨在加速 Dyadic 利用其微生物表達平台生產的重組蛋白產品在研究、診斷、培養肉和生命科學生物製造等行業的滲透，這些行業需要可靠、可擴展且具有成本效益的生長因子和功能性蛋白來源。Opes 已經為多家使用無血清細胞培養基的客户提供了樣品，應用於生命科學、食品和營養領域。</p>
</div><p>“This collaboration supports our commercial objectives by extending our recombinant protein portfolio in target markets with a partner that has strong, existing sector relationships within the sectors we serve,” said Joe Hazelton, President &amp; COO of Dyadic Applied BioSolutions. “Opes’ market presence and customer network are expected to help drive adoption of Dyadic’s cell culture media products into expanding markets and to further our shift from primarily development activities to broader commercial engagement.”</p>
<div class="lb-trans"><p>“這次合作通過與在我們服務的行業中擁有強大現有關係的合作伙伴擴展我們的重組蛋白產品組合，支持我們的商業目標，” Dyadic Applied BioSolutions 總裁兼首席運營官 Joe Hazelton 表示。“Opes 的市場存在和客户網絡預計將有助於推動 Dyadic 細胞培養基產品在不斷擴展的市場中的採用，並進一步推動我們從主要的開發活動轉向更廣泛的商業參與。”</p>
</div><p><strong>About Dyadic Applied BioSolutions</strong></p>
<div class="lb-trans"><p><strong>關於 Dyadic Applied BioSolutions</strong></p>
</div><p>Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com</p>
<div class="lb-trans"><p>Dyadic Applied BioSolutions 是一家全球生物技術公司，利用其專有的微生物平台生產重組蛋白，這些蛋白被銷售或授權給生命科學、食品與營養以及生物工業市場的合作伙伴。這些高質量的蛋白旨在幫助客户開發更高效、可擴展和可持續的產品。Dyadic 的 C1 和 Dapibus™表達系統支持靈活、具有成本效益的製造，並且是不斷增長的商業和合作項目組合的基礎。有關 Dyadic 的更多信息，請訪問 www.dyadic.com</p>
</div><p><strong>About Opes Diagnostics Limited</strong></p>
<div class="lb-trans"><p><strong>關於 Opes Diagnostics Limited</strong></p>
</div><p>Opes Diagnostics Limited is a United Kingdom–based provider of diagnostic tools, laboratory consumables, and biological reagents, with established customer relationships across Europe and other international markets. Opes offers commercialization support for a range of products used in biotechnology, diagnostics, and related fields.</p>
<div class="lb-trans"><p>Opes Diagnostics Limited 是一家總部位於英國的診斷工具、實驗室耗材和生物試劑的提供商，在歐洲和其他國際市場上擁有成熟的客户關係。Opes 為生物技術、診斷及相關領域的一系列產品提供商業化支持。</p>
</div><p><strong>Safe Harbor Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明的安全港</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.</p>
<div class="lb-trans"><p>本新聞稿包含根據《證券法》第 27A 節和《交易法》第 21E 節的定義的前瞻性聲明，包括 Dyadic 對未來事件或未來財務表現的預期、意圖、策略和信念，例如 Dyadic 臨牀試驗的成功及其蛋白生產平台的興趣、Dyadic 的研究項目和第三方合作，以及必要資金的可用性。前瞻性聲明涉及許多超出 Dyadic 控制的風險、不確定性或其他因素。這些因素包括但不限於以下內容：（i）Dyadic 的淨虧損歷史；（ii）市場和監管對 Dyadic 微生物蛋白生產平台及其他技術的接受；（iii）未能商業化 Dyadic 的微生物蛋白生產平台或其他技術；（iv）競爭，包括來自替代技術的競爭；（v）非臨牀研究和臨牀試驗的結果；（vi）Dyadic 的資本需求；（vii）全球經濟和金融狀況的變化；（viii）Dyadic 對信息技術的依賴；（ix）Dyadic 對第三方的依賴；（x）政府法規及環境、社會和治理問題；（xi）知識產權風險；（xii）Dyadic 遵守納斯達克證券市場上市標準的能力。有關可能導致 Dyadic 實際結果與其當前預期不同的風險的更完整描述，請參見 Dyadic 提交給 SEC 的 10-K 年報和 10-Q 季度報告中的 “風險因素” 部分，這些因素可能會不時在 Dyadic 定期向 SEC 提交的文件中更新，這些文件可在 SEC 網站和 www.dyadic.com 上獲取。所有前瞻性聲明僅在發佈之日有效，除非法律要求，Dyadic 不承擔在本新聞稿發佈後出於任何原因公開更新任何此類前瞻性聲明以使其與實際結果或 Dyadic 的預期變化相符的義務。</p>
</div><p>Media contacts:</p>
<div class="lb-trans"><p>媒體聯繫人：</p>
</div><p>Dyadic Applied BioSolutions:</p>
<div class="lb-trans"><p>Dyadic Applied BioSolutions：</p>
</div><p>Ping Rawson</p>
<div class="lb-trans"><p>Ping Rawson</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席財務官</p>
</div><p>Phone: (561) 743-8333</p>
<div class="lb-trans"><p>電話：（561）743-8333</p>
</div><p>Email: ir@dyadic.com</p>
<div class="lb-trans"><p>電子郵件：ir@dyadic.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UazJOU00zTXpJeE1qZzVJekl3TVRreU1UQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMTk2NSM3MzIxMjg5IzIwMTkyMTA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png"/></p>

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins | DYAI Stock News

Dyadic 應用生物解決方案公司建立商業合作伙伴關係，以加速 Dyadic 重組生長因子和培養基蛋白的採用 | DYAI 股票新聞